(Q43837340)
Statements
1 reference
FDA: Increased HBV reactivation risk with ofatumumab or rituximab (English)
1 reference
Mike Mitka
1 reference
1 October 2013
1 reference
1 reference
310
1 reference
16
1 reference
1664
1 reference
Identifiers
1 reference
1 reference